N-Desmethyl Clobazam

N-Desmethyl Clobazam Structure
N-Desmethyl Clobazam structure
Common Name N-Desmethyl Clobazam
CAS Number 22316-55-8 Molecular Weight 286.71300
Density 1.363 g/cm3 Boiling Point 601.8ºC at 760 mmHg
Molecular Formula C15H11ClN2O2 Melting Point N/A
MSDS N/A Flash Point 317.7ºC
Symbol GHS02 GHS07
GHS02, GHS07
Signal Word Danger

Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate.

Leg. Med. (Tokyo.) 12(6) , 300-4, (2010)

Clobazam is a benzodiazepine with anti-anxiety and anticonvulsant properties marketed in several countries. Norclobazam, a metabolite of clobazam, has similar pharmacological activity but weaker sedative and tranquilizing effect. The two drugs were detected b...

Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method.

J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 823(2) , 167-71, (2005)

A rapid and specific HPLC method has been developed and validated for simultaneous determination of clobazam, the anticonvulsant agent, and its major metabolite in human plasma. The sample preparation was a liquid-liquid extraction with tuloene yielding almos...

A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.

Brain Dev. 26(8) , 530-4, (2004)

N-desmethylclobazam (N-CLB), the major metabolite of clobazam (CLB), exerts a large influence on therapeutic and adverse effects of CLB. A substantial inter-individual variability has been observed in the ratios of N-CLB concentration/CLB dose and of the N-CL...

Analysis of clobazam and its active metabolite norclobazam in plasma and serum using HPLC/DAD.

Scand. J. Clin. Lab. Invest. 56(7) , 609-14, (1996)

This report describes a simple reversed-phase high-performance liquid chromatographic (HPLC) method with automated solid-phase extraction (SPE) for analysing clobazam and norclobazam concentrations in human serum or plasma. For the HPLC analysis the samples a...

Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy.

Dev. Med. Child Neurol. 48(7) , 612-5, (2006)

A four-year-old male with symptomatic generalized epilepsy presented with ataxia, eye rolling, and episodes of back arching which were of non-epileptic origin following the introduction of clobazam at 0.75mg/kg/day. Concurrent antiepileptic medication was lam...

HPLC method for simultaneous determination of clobazam and N-desmethylclobazam in human serum, rat serum and rat brain homogenates.

Biomed. Chromatogr. 3(2) , 79-81, (1989)

A method for simultaneous determination of clobazam (CBZ) and its active metabolite N-desmethylclobazam (DCBZ) in various biological samples by RP-HPLC with UV detection is described. The determination of both CBZ and DCBZ is performed without derivatization....

Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19.

Brain Dev. 26(1) , 63-6, (2004)

We describe the case of a 10-year-old girl with two epileptic seizures and subcontinuous spike-waves during sleep, who presented unusual side-effects related to clobazam (CLB) monotherapy. High plasma levels of N-desmethyl-clobazam (N-CLB), the major metaboli...

The metabolites N-desmethylclozapine and N-desmethylolanzapine produce cross-tolerance to the discriminative stimulus of the atypical antipsychotic clozapine in C57BL/6 mice.

Behav. Pharmacol. 22(5-6) , 458-67, (2011)

It has been previously shown that cross-tolerance to the discriminative stimulus properties of clozapine can be demonstrated with the drug discrimination paradigm. This study examined the ability of N-desmethylclozapine and N-desmethylolanzapine (metabolites ...

Clobazam and N-desmethylclobazam serum concentrations in endstage renal failure and hemodialysis.

Ann. Pharmacother. 28(7-8) , 966-7, (1994)

Disappointing results of increasing benzodiazepine dose after the development of anticonvulsant tolerance.

J. Neurol. Neurosurg. Psychiatr. 51(7) , 1008-9, (1988)